

PANCREATIC ADENOCARCINOMA – RESECTABLE

Tumor Subtypes in Subjects on FOLFIRINOX with Non-Metastatic Pancreatic Cancer

Clinical Trial Website: [NCT03977233](https://clinicaltrials.gov/ct2/show/study/NCT03977233)

Current Status: Recruiting

Design: This study evaluates how the genetic makeup of Pancreatic Ductal Adenocarcinoma (PDAC) can affect response to the FDA-approved chemotherapy treatment FOLFIRINOX when given before surgery to remove the tumor. Some but not all types of PDAC tumors can be surgically removed, especially if they are close to structures such as blood vessels or intestines. These types are treated with chemotherapy. Studies show that chemotherapy after surgical resection of PDAC tumors reduced the risk of the cancer returning.

Key Inclusion:

- Patients at least 18 years old
- Patients must have proven and measurable pancreatic cancer
- Able to tolerate therapy

Key Exclusion:

- Evidence of metastatic pancreatic cancer
- Prior chemotherapy, chemoradiotherapy, or surgery for pancreatic cancer
- Any other malignancies in the past 5 years

Principal Investigator: Ashwin Somasundaram, MD

Coordinator: [Catherine Griffin](#)

Phone: (984) 974-8771

PROMoting CLinical Trial EngagemEnt for Pancreatic Cancer App Study (PROCLAIM Study)

Clinical Trial Website: [NCT06252545](https://clinicaltrials.gov/ct2/show/study/NCT06252545)

Current Status: Recruiting

Description: This two-part, randomized trial seeks to identify and address barriers to enrollment of Black patients in pancreatic cancer clinical trials by conducting interviews and creating a culturally-informed mobile health application to promote participation.

Key Inclusion:

- Patients at least 18 years old
- Patients must identify as Black
- Have newly diagnosed or progressive pancreatic cancer
- Have access to a mobile device

Key Exclusion:

- Inability to read and speak English
- Dementia altered mental status or a psychiatric condition prohibiting informed consent
- Active participation in a therapeutic clinical trial

Principal Investigator: Jen Jen Yeh, MD

Coordinator: [Brent Henderson](#)

Phone: 919-966-7706